Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen |
Moon, Seung Kee
(Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.)
Park, So Ra (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Park, Ami (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Oh, Hyun Mi (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Shin, Hyun Jung (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Jeon, Eun Ju (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Kim, Seiwhan (Bio Medicine Lab., CKD Research Institute, ChongKunDang Pharm.) Park, Hyun June (Graduate Program of Bioengineering, Seoul National University) Yeon, Young Joo (The Institute of Molecular Biology and Genetics, Seoul National University) Yoo, Young Je (Graduate Program of Bioengineering, Seoul National University) |
1 | Back, H., Suk, K.H., Kim, Y.H., and Cha, S.H. (2002). An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res. 30, e18-e26. DOI |
2 | Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B., Henner, D., Wong, W.L., Rowland, A.M., Kotts, C., Carver, M.E., and Shepard, H.M. (1992). Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89, 4285-4289. DOI |
3 | Chatellier, J., Van Regenmortel, M.H., Vernet, T., and Altschuh, D. (1996). Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J. Mol. Biol. 264, 1-6. DOI |
4 | Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H.W., McKay, P., de Vos, A.M., and Lowman, H.B. (1999). Selection and analysis of an optimized anti-VEGF antibody crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865-881. DOI |
5 | Genentech, Inc. (2005). Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies. US6949245 (US Patent). |
6 | Gerstner, R.B., Carter, P., and Lowman, H.B. (2002). Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J. Mol. Biol. 321, 851-862. DOI |
7 | Gong, S.J., Jin, C.J., Rha, S.Y., and Chung, H.C. (2004). Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 214, 215-224. DOI |
8 | Hawkins, R.E., Russell, S.J., Baier, M., and Winter, G. (1993). The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J. Mol. Biol. 234, 958-964. DOI |
9 | Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M., and Ullrich, A. (1989). p185 HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172. DOI |
10 | Johnsson, B., Löfås, S., and Lindquist, G.. (1991). Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Analyt. Biochem. 198, 268-277. DOI |
11 | Kabat, E.A., and Wu, T.T. (1991). Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL gene, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J. Immunol. 147,1709-1719. |
12 | Kelley, R.F., and O'Connell, M.P. (1993). Thermodynamic analysis of an antibody functional epitope. Biochemistry 32, 6828-6835. DOI |
13 | Kim, J.W., Kim, H.P., Im, S.A., Kang, S., Hur, H.S., Yoon, Y.K., Oh, D.Y., Kim, J.H., Lee, D.S., Kim, T.Y., and Bang, Y.J. (2008). The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272, 296-306. DOI |
14 | Lesley, J., Hascall V.C., Tammi, M., and Hyman, R. (2000). Hyaluronan binding by cell surface CD44. J. Biol. Chem. 275, 26967-26975. |
15 | Lowe, D., Wilkinson T., and Vaughan, T.J., (2012). Affinity maturation approaches for antibody lead optimization. in Antibody Drug Discovery, Wood C.R., (London, UK : Imperial College Press). pp. 85-120. |
16 | O'Brien, N.A., Browne, B.C., Chow, L., Wang, Y., Ginther, C., Arboledal, J., Duffy, M.J., Crown, J., O'Donovan, N., and Slamon, J.D. (2010). Activated phosphoinositide 3-kinase/AKT signaling confers resistance to Trastuzumab but not Lapatinib. Mol. Cancer Ther. 9, 1489-2211. DOI |
17 | Macdonald, R.A., Hosking, C.S., and Jones, C.L. (1988). The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods. 106,191-194. DOI |
18 | Mayumi, O., and Michihiko, K. (2006). Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to Gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 12, 7242-7251. DOI |
19 | Nicolas, W., Véronique, D.H., and Martine, J.P. (2008). HER2- positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin. Breast Cancer 8, 38-49. DOI |
20 | Oh, M.Y., oung, Joo, H.Y., Hur, B.U., Jeong, Y.H., and Cha, S.H. (2007). Enhancing phage display of antibody fragments using gIII-amber suppression. Gene 386, 81-89. DOI |
21 | Phumyen, A., Jumnainsong, A., and Leelayuwat, C. (2012). Improved binding activity of antibodies against major histocompatibility complex Class I chain-related gene A by phage display technology for cancer-targeted therapy. J. Biomed. Biotechnol. 2012,1-8. |
22 | Rajpal, A., Beyaz, N., Haber, L., Cappuccilli, G., Yee, H., Bhatt, R.R., Takeuchi, T., Lerner, R.A., and Crea, R. (2005). A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc. Natl. Acad. Sci. USA 102, 8466-8471. DOI |
23 | Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E. Jr., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684. DOI |
24 | Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M., and Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26, 60-70. |
25 | Schier, R., McCall, A., Adams, G.P., Marshall, K.W., Merritt, H., Yim, M., Crawford, R.S., Weiner, L.M., Marks, C., and Marks, J.D. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263, 551-567. DOI |
26 | Shepard, H.M., Lewis, G.D., Sarup, J.C., Fendly, B.M., Maneval, D., Mordenti, J., Figari, I., Kotts, C.E., Palladino, M.A. Jr, Ullrich, A., et al. (1991). Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-127. DOI |
27 | Sidhu, S.S, Lowman, H.B., Cunningham, B.C., and Wells, J.A. (2000). Phage display for selection of novel binding peptides. Methods Enzymol. 328, 333-363. DOI |
28 | Song, S.Y., Hur, B.U., Lee, K.W., Choi, H.J., Kim, S.S., Kang, K., and Cha, S.H. (2009). Successful application of the dual-vector system II in creating a reliable phage-displayed combinatorial Fab library. Mol. Cells 27, 313-319. DOI |
29 | Wang, Z., Wang, Y., Li, Z., Li, J., and Dong, Z. (2000). Humanization of a mouse monoclonal antibody neutralizing TNF-alpha by guided selection. J. Immunol. Methods 241, 171-184. DOI |
30 | Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., and Arteaga, C.L. (2002). Herceptin-induced inhibition of phosphatidylinositol- 3 kinase and Akt is required for antibodymediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141. |
31 | Yoon, S.O., Lee, T.S., Kim, S.J., Jang, M.H., Kang. Y.J., Park, J.H., Kim, K.S., Lee, H.S., Ryu, C.J., Gonzales, N.R., et al. (2006). Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985-6992. DOI |
![]() |